Cargando…

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy

SIMPLE SUMMARY: The clinical use of immunoadjuvants is limited by transient responses and various side effects. This study investigated the multi-adjuvant approach of combining a TLR 7/8 agonist (522) and a STING agonist (DMXAA) to generate a robust anticancer immune response. Immunization with oval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhatnagar, Shubhmita, Revuri, Vishnu, Shah, Manan, Larson, Peter, Shao, Zekun, Yu, Daohai, Prabha, Swayam, Griffith, Thomas S., Ferguson, David, Panyam, Jayanth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777055/ https://www.ncbi.nlm.nih.gov/pubmed/36551577 http://dx.doi.org/10.3390/cancers14246091

Ejemplares similares

Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)
por: Khanna, Vidhi, et al.
Publicado: (2021)

Incorporation of paclitaxel in mesenchymal stem cells using nanoengineering upregulates antioxidant response, CXCR4 expression and enhances tumor homing
por: Prabha, Swayam, et al.
Publicado: (2023)

Enhancing Anticancer Efficacy of Chemotherapeutics Using Targeting Ligand-Functionalized Synthetic Antigen Receptor-Mesenchymal Stem Cells
por: Nethi, Susheel Kumar, et al.
Publicado: (2023)

Improving Payload Capacity and Anti-Tumor Efficacy of Mesenchymal Stem Cells Using TAT Peptide Functionalized Polymeric Nanoparticles
por: Moku, Gopikrishna, et al.
Publicado: (2019)

Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma
por: Hajiabadi, Sare, et al.
Publicado: (2023)

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
por: Motedayen Aval, Leila, et al.
Publicado: (2020)

Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy
por: Go, Eun-Jin, et al.
Publicado: (2020)

Combination of STING Pathway Agonist With Saponin Is an Effective Adjuvant in Immunosenescent Mice
por: Vassilieva, Elena V., et al.
Publicado: (2019)

Tumor-targeted delivery of a STING agonist improves cancer immunotherapy
por: Wu, You-tong, et al.
Publicado: (2022)

TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN
por: Temizoz, Burcu, et al.
Publicado: (2015)

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation
por: Zhang, Bo-Dou, et al.
Publicado: (2022)

TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
por: Luchner, Marina, et al.
Publicado: (2021)

STING Agonists as Cancer Therapeutics
por: Amouzegar, Afsaneh, et al.
Publicado: (2021)

Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy
por: Shae, Daniel, et al.
Publicado: (2019)

Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
por: Zheng, Huan, et al.
Publicado: (2022)

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
por: Su, Ting, et al.
Publicado: (2022)

Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2020)

A novel defined TLR3 agonist as an effective vaccine adjuvant
por: Ko, Kwang Hyun, et al.
Publicado: (2023)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
por: Sanchez Alberti, Andrés, et al.
Publicado: (2017)

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
por: Smirnov, DV, et al.
Publicado: (2013)

Correction to: Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2021)

BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant
por: Kaushik, Deepender, et al.
Publicado: (2020)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA
por: Chang, Jiajia, et al.
Publicado: (2023)

STING activation in cancer immunotherapy
por: Su, Ting, et al.
Publicado: (2019)

Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy
por: Wang, Bin, et al.
Publicado: (2022)

Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy
por: Zhou, Ying, et al.
Publicado: (2022)

Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives
por: Huang, Cuiqing, et al.
Publicado: (2023)

STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy
por: Zhou, Lei, et al.
Publicado: (2023)

Differential Adjuvant Activities of TLR7 and TLR9 Agonists Inversely Correlate with Nitric Oxide and PGE(2) Production
por: Lee, Jinhee, et al.
Publicado: (2015)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
por: Younes, Ahmed I., et al.
Publicado: (2020)

Trial watch: STING agonists in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Effects of STING stimulation on macrophages: STING agonists polarize into “classically” or “alternatively” activated macrophages?
por: Ohkuri, Takayuki, et al.
Publicado: (2017)

ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
por: Jang, Su Chul, et al.
Publicado: (2021)

Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer
por: Esteves, Ana M., et al.
Publicado: (2021)

Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma
por: Zhang, Ziyuan, et al.
Publicado: (2022)

Remodeling of Tumor Microenvironment by Nanozyme Combined cGAS–STING Signaling Pathway Agonist for Enhancing Cancer Immunotherapy
por: Dong, Wenpei, et al.
Publicado: (2023)

Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor
por: Rajendrakumar, Santhosh Kalash, et al.
Publicado: (2018)

TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
por: Lu, Hailing
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_d41jtcgo2asaqk8hu95c6ueo95